Send to

Choose Destination
Gynecol Oncol Rep. 2017 Jun 27;21:78-80. doi: 10.1016/j.gore.2017.06.013. eCollection 2017 Aug.

Elevated tumor mutational burden and prolonged clinical response to anti-PD-L1 antibody in platinum-resistant recurrent ovarian cancer.

Author information

Department of Obstetrics and Gynecology, University of Washington, Seattle, WA, United States.
Foundation Medicine, Cambridge, MA, United States.


•We report an ovarian cancer patient with a prolonged response to immunotherapy.•Comprehensive genomic profiling may detect patients who benefit from immunotherapy.•Mutational burden thresholds for ovarian cancer may be lower than other cancers.

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center